Travere Therapeutics
NASDAQ · TVTX·San Diego, CA·Mid-cap·Approved
Commercial-stage biotech focused on rare kidney and metabolic diseases. Lead product FILSPARI (sparsentan) is approved for IgA nephropathy with sNDA pending for FSGS. Pipeline includes pegtibatinase for classical homocystinuria.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Travere Therapeutics Corporate Overview January 2026 | Corporate overview | January 12, 2026 | 42 |